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PGD2 is the major mediator released by mast cells during allergic responses, and it acts through two different receptors, the D
prostanoid receptor 1 (DP1) and DP2, also known as CRTH2. Recently, it has been shown that PGD2 inhibits the migration of
epidermal Langerhans cells to the skin draining lymph nodes (LNs) and affects the subsequent cutaneous inflammatory reaction.
However, the role of PGD2 in the pulmonary immune response remains unclear. Here, we show that the intratracheal instillation
of FITC-OVA together with PGD2 inhibits the migration of FITC lung DC to draining LNs. This process is mimicked by the DP1
agonist BW245C, but not by the DP2 agonist DK-PGD2. The ligation of DP1 inhibits the migration of FITC-OVA DCs only
temporarily, but still inhibits the proliferation of adoptively transferred, OVA-specific, CFSE-labeled, naive T cells in draining
LNs. These T cells produced lower amounts of the T cell cytokines IL-4, IL-10, and IFN- compared with T cells from mice that
received FITC-OVA alone. Taken together, our data suggest that the activation of DP receptor by PGD2 may represent a pathway
to control airway DC migration and to limit the activation of T cells in the LNs under steady state conditions, possibly contributing
to homeostasis in the lung. The Journal of Immunology, 2003, 171: 3936–3940.
P rostaglandins are small lipid molecules that play an im-portant role in the modulation of inflammatory diseases.They are produced from arachidonic acid, which is con-
verted to PGH2, a common precursor of several PGs, by the cy-
clooxygenase enzymes COX-13 and COX-2. PGH2 can then be
converted into a series of PGs, including PGE2 and PGD2 (1).
PGD2 binds two receptors: the D prostanoid receptor 1 (DP1)
(2) and DP2, also known as CRTH2 (3), which is preferentially
expressed on Th2 cells, eosinophils, and basophils. PGD2 has been
associated with the development of pulmonary inflammatory diseases
such as asthma (4). The major sources of PGD2 include activated mast
cells (5), Th2 cells (6), and dendritic cells (DCs) (7).
DCs are APCs that can initiate immune responses after they
have captured Ags in peripheral tissues and have migrated to the T
cell area in draining lymph nodes (LNs). The mechanisms that
control DC migration from the periphery to the LNs are not com-
pletely understood. Chemokines and the pattern of chemokine re-
ceptors expressed by DCs seem to play a crucial role. However,
more recently other factors, such as lipid mediators, also play a
critical role in the migration of DCs from the periphery to the LNs.
Leukotriene C4 (LTC4) and PGE2 promote the migration of DCs
from the skin to the LNs (8, 9), whereas PGD2 has the opposite
effect and prevents the departure of DCs from epidermis to drain-
ing LNs (10).
Here we show that the migration of airway DCs to the thoracic
LNs in steady state conditions is mediated through DP1, not DP2,
activation. Moreover, administration of the DP1 agonist BW245C
reduces the proliferation of Ag-specific T cells and the cytokine
production by LN cells.
Materials and Methods
Reagents and Abs
PGD2, BW245C, DK-PGD2 (13,14-dihydro-15-keto-PGD2), and PGD2
were purchased from Cayman Chemicals (Ann Arbor, MI). FITC-labeled
OVA and CFSE were obtained from Molecular Probes (Eugene, OR). Col-
lagenase type II was purchased from Worthington Biochemical Corp.
(Lakewood, NJ). DNase I was obtained from Sigma-Aldrich (Zwijndrecht,
The Netherlands). The PE-conjugated anti-I-Ad/I-Ed (M5/114.5.2) was ob-
tained from BD PharMingen (Heidelberg, Germany). The PE-conjugated
KJ1-26 (clonotypic OVA-TCR) was purchased from Caltag Laboratories
(Burlingame, CA). The allophycocyanin-labeled anti-CD4 (RM4-5) and
anti-CD11c (HL3) were obtained from BD PharMingen. The endotoxin
level of FITC-OVA determined by a Limulus amebocyte assay (BioWhit-
taker, Walkersville, MD) was 0.001 g, which was previously reported
not to affect DCs (11).
Mice
BALB/c mice (6–8 wk old) were purchased from Harlan (Zeist, The Neth-
erlands). OVA-TCR transgenic mice (DO11.10) on a BALB/c background
were bred at Erasmus University (Rotterdam, The Netherlands).
Intratracheal administration of reagents
Mice were anesthetized by i.p. injection of avertin. Eighty microliters of
FITC-OVA (10 mg/ml), with or without BW245C, DK-PGD2, or PGD2,
was administered intratracheally under direct vision through the opening
vocal cords using a 18-gauge polyurethane catheter connected to the outlet
of a micropipette as previously described (12). Control mice received 80 l
of PBS/DMSO.
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Preparation of single-cell suspension from LNs
At several time points following FITC-OVA instillation, animals were
killed by an overdose of avertin. Thoracic draining LN cells and lung cells
were obtained as previously described (13). Briefly, thoracic LNs or lungs
were digested for 1 h at 37°C in RPMI 1640 containing 5% FCS, 1 mg/ml
of collagenase II, and 2 IU/ml of DNase I. The reaction was stopped by
addition of PBS containing 10 mM EDTA. LN cells (95% viability) were
washed, stained with anti-MHC class II and anti-CD11c Abs, and analyzed
by flow cytometry for FITC positivity. Dead cells and debris were excluded
using propidium iodide.
Effect of BW245C on T cell proliferation in thoracic LNs
Because the frequency of OVA-specific T cells is very low in immunized
animal, naive T cells purified from DO11.10 mice were adoptively trans-
ferred into BALB/c mice. Briefly, LNs and spleen were harvested from
DO11.10 mice and homogenized, and after RBC lysis, cell suspensions
were labeled with CFSE as previously described (14). On day 2, 10 
106 live cells were injected i.v. in the lateral tail vein of each mouse (day
2). On day 0, mice received an intratracheal injection of FITC-OVA (0.1,
1, or 10 mg/ml) with or without 100 M BW245C (final concentration, 8
nmol). On day 4, thoracic LNs were collected and stained for the presence
of KJ1-26CD4 OVA-specific T cells. Some of the LN cells (2  105
cells/well in triplicate) were resuspended in RPMI 1640 containing 5%
FCS and antibiotics and placed in round-bottom, 96-well plates. Four days
later, supernatants were harvested and analyzed for the presence of IL-4,
IL-10, and IFN- (BD PharMingen).
Statistical analysis
For all experiments the difference between the various groups was calcu-
lated using the Mann-Whitney U test for unpaired data. Differences were
considered significant at p  0.05.
Results
PGD2 impairs lung DC migration to draining LNs through DP1
As shown in Fig. 1A, migrating MHCII/CD11c/FITC DCs are
detected in the thoracic LNs 2 days after the instillation of FITC-
OVA. The OVA-induced migration of DCs was strongly inhibited
by PGD2. To identify which of the PGD2 receptors (DP1 or DP2)
was involved in reducing DC migration to the LNs, FITC-OVA
was injected intratracheally together with the DP1 agonist
BW245C or the DP2 agonist DK-PGD2. BW245C dose-depen-
dently inhibited the migration of lung DCs to thoracic LNs
(BW245C/FITC; Fig. 1, A and B). Interestingly, the migration of
lung DCs was not affected by DK-PGD2 (Fig. 1, A and C), sug-
gesting that the migration of lung DCs to the nodes was mediated
mainly through DP1, not DP2. As the maximal effect was obtained
with a dose of 100 M BW245C, additional experiments were
performed with this dose. Moreover, to exclude a possible toxic
effect of BW245C on lung DCs, total lungs were digested and
stained for MHCIICD11c DCs. The total number of DCs de-
tected in the lungs of animals that were instilled with FITC-OVA
alone and that in animals given BW245C/FITC-OVA was not sig-
nificantly different (52,520  16,678 and 74,080  8,120, respec-
tively; Fig. 2), indicating that the effect induced by BW245C was
not due to cell death, but, rather, to the immobilization of DCs in
the airways.
FIGURE 1. Effects of PGD2, BW245C, and DK-PGD2 on lung DC migration to the thoracic draining LNs. On day 0, mice were instilled intratracheally
with 10 mg/ml FITC-OVA with or without different doses of PGD2, BW245C (A and B), and DK-PGD2 (A and C). On day 2, the presence of FITC
migrating DCs in thoracic draining LNs was analyzed by flow cytometry. Results are shown as the mean  SD and are representative of 8–12 mice/group.
FIGURE 2. Effect of BW245C on lung DCs. On day 0, mice were in-
stilled intratracheally with 10 mg/ml FITC-OVA with or without BW245C.
On day 2, lungs were enzymatically digested and stained for the presence
of FITC MHC II CD11c DCs. Results are shown as the mean  SD
and are representative of 10–12 mice/group.
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BW245C temporarily blocks DC migration in vivo
As the selective activation of DP1 impaired lung DC migration, we
studied how long a single injection of BW245C would affect the
migration of endogenous DCs to the thoracic LNs. For this pur-
pose, BALB/c mice were injected intratracheally with 10 mg/ml of
FITC-OVA with or without 100 M BW245C. Mice were killed
1, 2, 4, or 7 days later. Compared with mice that received FITC-
OVA alone, the number of migrating FITC DCs was reduced up
to day 2 in mice that received an instillation of BW245C. How-
ever, no difference was observed in the number of FITC DCs
reaching draining LNs at 4 or 7 days in mice that received either
FITC-OVA alone or FITC-OVA containing BW245C (Fig. 3).
BW245C impairs OVA-specific T cell proliferation in thoracic
LNs
As BW245C inhibited the migration of endogenous lung DCs, we
next hypothesized that it could also impact T cell activation in
thoracic LNs. To test this we first set up an experiment in which
BALB/c mice were adoptively transferred with cells from
DO11.10 mice on day 2 and were injected with increasing doses
of FITC-OVA (0.1, 1, and 10 mg/ml) with or without 100 M
BW245C on day 0. Mice were killed on day 4, and cell divisions
were evaluated by flow cytometry. As expected, in mice that re-
ceived the higher dose of FITC-OVA (10 mg/ml), T cells had
undergone seven divisions (Fig. 4). Interestingly, the less FITC-
OVA the mice received, the fewer T cells entered into divisions.
BW245C reduced the number of T cells entering into division
without affecting the number of cell divisions independently from
the dose of FITC-OVA. However, the effect of BW245C on T cell
proliferation appeared to be dependent on the dose of FITC-OVA.
The stronger effect was obtained with the lower concentration of
FITC-OVA (0.1 mg/ml). We chose this dose of OVA to perform
the following experiment.
BW245C reduces cytokine production by draining LN T cells
We next investigated whether the administration of BW245C
could affect FITC-OVA-induced cytokine production by thoracic
LN T cells. In these experiments, 4 days following the injection of
FITC-OVA with or without BW245C, thoracic LN cells were col-
lected and cultured for 4 days in the absence of exogenous OVA.
Supernatants were then tested for the presence of IL-4, IL-10, and
IFN-. As shown in Fig. 5, compared with levels in mice that
received FITC-OVA alone, treatment with BW245C reduced the
amounts of all cytokines tested.
Discussion
The migration of DCs from the periphery to draining LNs is a key
step leading to the initiation of immune responses or to tolerance,
depending on their maturation stage (15, 16). The molecular events
that induce or control DC migration have been the purpose of
extensive research in the past few years. The factors involved in
the migration of Langerhans cells, which are known to have low
turnover (17), have been widely studied. The presence of inflam-
matory cytokines, such as TNF- or IL-1, in their microenviron-
ment induces the departure of Langerhans cells (18). More re-
cently, it has been shown that some products of arachidonic acid
(LTC4 and PGE2) could up-regulate the chemokine-driven migra-
tion of DCs (8, 9, 19). However little is known about the migration
of DCs from other organs, such as the lung. In this study we show
that airway DCs migrate very efficiently to thoracic LNs following
intratracheal injection of FITC-OVA, as previously reported (20).
Interestingly, the OVA-induced migration was inhibited by
BW245C, a selective agonist for DP1, and not by the DP2 agonist,
DK-PGD2. DP1 activation has been reported to inhibit Langerhans
FIGURE 3. Kinetics of action of BW245C on lung DC migration to
draining LNs. On day 0, mice were instilled intratracheally with 10 mg/ml
FITC-OVA with or without 100 M BW245C. On days 1, 2, 4, and 7
following instillation, thoracic LNs were digested and stained for the pres-
ence of FITC MHC II CD11c DCs. Results are shown as the mean 
SD and are representative of 10 mice/group.
FIGURE 4. Effect of BW245C on DC-induced T cell proliferation in
draining LNs. On day2, mice were injected i.v. with OVA-specific naive
T cells from DO11.10 mice. On day 0, mice were instilled intratracheally
with increasing doses of FITC-OVA (0.1, 1, and 10 mg/ml; u) in the
absence or the presence of 100 M BW245C (f). On day 4, the prolifer-
ation of KJ1–26 CD4 CFSE T cells was analyzed by flow cytometry.
Results show one representative experiment with 10–12 mice/group.
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cell migration in a model of parasite infection (10). However, to
our knowledge, this is the first report showing the inhibition of DC
migration with a high turnover (17) and under steady state condi-
tions. The direct effect of BW245C on lung DCs remains to be
determined. Lung DCs are difficult to purify in sufficient amounts
to perform functional studies. However, we have evidence that in
vitro treatment of bone marrow-derived DCs with BW245C re-
duces their potential to migrate from the bronchoalveolar lavage
fluid compartment to the lung draining LNs in vivo (our unpub-
lished observations and Ref. 14). However, an indirect effect of the
agonist on airway DCs cannot be ruled out in this study, as
BW245C was administered into the trachea of mice.
As the migration of airway OVA-loaded DCs reaching the LNs
was less strong and delayed over time by BW245C treatment, we
looked at the effect of BW245C administration on T cell activa-
tion. In mice that received only FITC-OVA, T cells from the LNs
had already undergone eight divisions by day 4 following instil-
lation. These data are in agreement with those from other groups
showing that under steady state conditions, DCs reaching the LNs
show high levels of Ag presentation to specific T cells (21). How-
ever, when mice received BW245C together with FITC-OVA, the
number of T cells recruited into divisions was lower, but the num-
ber of divisions undergone by some T cells was not affected. More-
over, the levels of all cytokines produced by T cells of BW245C-
treated mice were reduced compared with those in mice instilled
with only FITC-OVA. This suggests that BW245C can impair the
primary activation of T cells by DCs within draining LNs. The
lower T cell response observed in BW245C-treated mice may be
explained 1) by the lower number of DCs reaching the LNs or 2)
by the fact that BW245C could limit the maturation of airway DCs
by affecting the levels of costimulatory molecules or/and the ex-
pression of the chemokine receptor CCR7 whose ligands (CCL19/
CCL21) are known to direct mature DCs to draining LNs (22). The
unresponsiveness of DCs to the ligands of CCR7 may subse-
quently affect the primary immune response, as previously re-
ported in plt mice (23) or CCR7-deficient mice (24).
Our data show for the first time that PGD2, through selective
activation of DP1, can reduce the migration of lung DCs. More-
over, T cell activation within the thoracic draining LNs was also
significantly reduced. This is another example of interference of
DC migration by lipid mediators. Regulation of DC migration by
PGD2 or its metabolites might have a physiological meaning.
PGD2 is produced by mast cells and APCs, such as alveolar mac-
rophages. Under steady state conditions, macrophages might se-
crete PGD2 to suppress DC and T cell activation (25). During
inflammation, PGE2 and LTC4 are produced and induce differen-
tiation and maturation of tissue-resident DCs (8, 19). Under these
conditions, the anti-inflammatory effects of PGD2 are overridden
by the proinflammatory effects of PGE2, LTC4, and proinflamma-
tory cytokines. Also, at the resolution of inflammation, COX-2
enzyme mainly generates PGD2, rather than PGE2 (26). The re-
lease of PGD2 might suppress DC migration to prevent further
immune stimulation, thus contributing to the resolution of inflam-
mation. Additional experiments will be necessary to understand
the differential effects of PGs on DC functions. These data may
have important consequences to improve the treatments of lung
diseases such as asthma, where the migration of DCs to the tho-
racic LNs is known to induce or enhance the Ag-specific Th2
response (12, 14, 27, 28).
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